Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C. Bhatt SP, et al. Among authors: crim c. Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:351-365. doi: 10.2147/COPD.S117373. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28176907 Free PMC article. Clinical Trial.
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM. Dransfield MT, et al. Among authors: crim c. Lancet Respir Med. 2013 May;1(3):210-23. doi: 10.1016/S2213-2600(13)70040-7. Epub 2013 Apr 12. Lancet Respir Med. 2013. PMID: 24429127 Clinical Trial.
Fluticasone furoate and vilanterol for COPD - authors' reply.
Dransfield MT, Lettis S, Barnhart F, Crim C, Calverley PM. Dransfield MT, et al. Among authors: crim c. Lancet Respir Med. 2013 Jul;1(5):e21-2. doi: 10.1016/S2213-2600(13)70125-5. Epub 2013 Jul 8. Lancet Respir Med. 2013. PMID: 24429207 No abstract available.
Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ. Dransfield MT, et al. Among authors: crim c. Respir Med. 2014 Aug;108(8):1171-9. doi: 10.1016/j.rmed.2014.05.008. Epub 2014 Jun 19. Respir Med. 2014. PMID: 24998880 Free article. Clinical Trial.
A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C. Siler TM, et al. Among authors: crim c. Respir Med. 2017 Feb;123:8-17. doi: 10.1016/j.rmed.2016.12.001. Epub 2016 Dec 2. Respir Med. 2017. PMID: 28137501 Free article. Clinical Trial.
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Lettis S, Manchester P, Martin N, Midwinter D, Morris A, Pascoe SJ, Singh D, Wise RA, Martinez FJ. Lipson DA, et al. Among authors: crim c. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC. Am J Respir Crit Care Med. 2020. PMID: 32162970 Free PMC article. Clinical Trial.
132 results